在博茨瓦纳获得COVID-19疫苗的公平准入:一个范围审查
John T Tlhakanelo1,2, John Ele-Ojo Ataguba2,3,4,5, Vincent Pagiwa6
1Department of Family Medicine and Public Health, Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Frontiers in health services
|August 13, 2025
概括
博茨瓦纳实现了高COVID-19疫苗接种率,其中80.6%的人至少接种了一剂. 现有免疫计划的挑战影响了疫苗的发放和获取,特别是在偏远地区.
科学领域:
- 公共卫生 公共卫生
- 疫苗学 疫苗学 疫苗学
- 卫生系统研究 卫生系统研究
背景情况:
- 博茨瓦纳在2021年3月至2022年3月期间获得了260万剂COVID-19疫苗 (76%购买,24%捐赠).
- 全球市场的复杂性影响了疫苗采购和分销.
研究的目的:
- 为了汇总博茨瓦纳COVID-19疫苗接种模式的证据.
- 分析在博茨瓦纳的COVID-19疫苗犹和采用情况.
- 为中等收入国家提供有关疫苗策略的见解.
主要方法:
- 对总部位于博茨瓦纳的英语同行评审和灰色文献进行了范围审查.
- 搜索的数据库包括Medline,CINAHL,科学网,PubMed,Scopus和谷歌学者.
- 由于研究异质性,使用了叙事综合方法.
主要成果:
- 截至2021年12月31日,80.6%的目标人群至少接种了一剂COVID-19疫苗,71.9%的目标人群接种了全部疫苗.
- 成年人接受COVID-19疫苗的比例为73.4%,与男性性别,并发症,非限制性宗教信仰和年龄较大的年龄组 (55-64岁) 有积极联系.
- 疫苗接种面临着与运输,人力资源和库存不足有关的挑战,这与现有的疫苗接种扩展计划 (EPI) 结构固有.
结论:
- 地区级疫苗接种计划的表现不佳和外展服务不足加剧了疫苗接种差异.
- 加强医疗保健基础设施和扩大外展是达到服务不足的人口的关键.
- 政府实体和私营部门之间的合作加强了疫苗接种.
相关概念视频
01:51Vaccinations
45.3K
Overview
45.3K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
01:03Drug Control Governance: Regulatory Bodies and Their Impact
241
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
241
01:29Bias in Epidemiological Studies
676
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
676
01:30Primary Healthcare Services
1.5K
Primary care promotes wellness and prevents disease. This care includes health promotion, education, protection (such as immunizations), early disease screening, and environmental considerations. Settings providing this type of healthcare include physician offices, public health clinics, school nursing, and community health nursing.
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
1.5K
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K